The Johns Hopkins spinout has raised cash from OUP as it looks to move its first candidate, targeting skin itch complications, into the clinic.

Escient Pharmaceuticals, a US-based drug developer spun out of Johns Hopkins University, closed a $77.5m series B round on Monday backed by spinout-focused investment firm Osage University Partners (OUP). Sanofi Ventures, the corporate venturing arm of pharmaceutical firm Sanofi, and Cowen Healthcare Investments (CHI) co-led the round, with further participation from Redmile Group and Perceptive…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.